Pediatrics 10marks questions with elaborative answer

Asking for Preferences

Reading File

Finding Sources

Reading File

Finding Sources

Here are 10 high-yield Pediatrics questions with elaborative answers for MBBS Final Year exams, covering all major topics:

PEDIATRICS - 10 Marks Questions with Elaborative Answers

Q1. Discuss Neonatal Jaundice - causes, assessment, and management.

Introduction

Jaundice (icterus neonatorum) is the yellow discoloration of skin and sclera due to hyperbilirubinemia. It becomes clinically visible when serum bilirubin exceeds 5 mg/dL. Nearly every newborn develops unconjugated bilirubin >1 mg/dL (the adult upper limit) in the first week of life.

Bilirubin Metabolism

Bilirubin is formed from breakdown of heme proteins (mainly hemoglobin)
Unconjugated (indirect) bilirubin binds albumin and is transported to the liver
Hepatic glucuronyl transferase conjugates it to direct bilirubin
Excreted in bile; intestinal flora converts it to urobilinogen

Three Mechanisms of Neonatal Jaundice

Increased bilirubin production - due to high fetal RBC turnover
Decreased clearance and excretion - immature liver enzyme activity
Increased enterohepatic resorption - lack of gut flora, increased beta-glucuronidase activity

Classification

Type	Onset	Cause
Physiologic jaundice	Day 2-3, resolves by day 7 (term) or day 14 (preterm)	Normal neonatal physiology
Breast milk jaundice	Week 2-3, can persist 3-12 weeks	Beta-glucuronidase in breast milk
Pathologic jaundice	Within 24 hours / prolonged	ABO/Rh incompatibility, G6PD deficiency, sepsis, biliary atresia

Causes of Unconjugated Hyperbilirubinemia

Hemolysis: ABO incompatibility, Rh incompatibility, G6PD deficiency, hereditary spherocytosis, birth trauma (cephalhematoma)
Non-hemolytic: Physiologic, breast milk jaundice, Crigler-Najjar syndrome, Gilbert syndrome

Causes of Conjugated (Direct) Hyperbilirubinemia - Always Pathologic

Biliary atresia (most important - surgery within 60 days)
Neonatal hepatitis
TORCH infections (CMV, rubella, toxoplasmosis)
Total parenteral nutrition cholestasis
Alagille syndrome

Assessment - Kramer's Rule

Bilirubin level estimated by cephalocaudal progression of jaundice:

Zone 1 (face): ~5 mg/dL
Zone 2 (chest to umbilicus): ~9 mg/dL
Zone 3 (umbilicus to thighs): ~12 mg/dL
Zone 4 (knees to ankles): ~15 mg/dL
Zone 5 (palms/soles): >18 mg/dL

Confirmatory: Serum total and direct bilirubin. Use transcutaneous bilirubinometer for screening.

Complications - Kernicterus

Unconjugated bilirubin crosses BBB (especially when albumin binding saturated)
Deposits in basal ganglia, hippocampus, cerebellum
Acute: lethargy, high-pitched cry, opisthotonus, seizures
Chronic: choreoathetosis, hearing loss, upward gaze palsy, intellectual disability

Management

Phototherapy (first-line): Blue-green light (430-490 nm) converts bilirubin to water-soluble photoisomers excreted in bile/urine. Indications based on Bhutani nomogram.
Exchange transfusion: For bilirubin approaching toxic levels, hemolytic disease; removes sensitized RBCs, bilirubin, and maternal antibodies.
Treat underlying cause: If Rh disease - IV immunoglobulin; if biliary atresia - Kasai portoenterostomy within 60 days.

Q2. Describe the clinical features, complications, and management of Protein-Energy Malnutrition (PEM) in children.

Introduction

PEM (also called Severe Acute Malnutrition - SAM) is the most common nutritional disorder worldwide, causing impairment of growth, immunity, and organ function. It occurs when protein and/or caloric intake is insufficient relative to requirements.

Classification

Feature	Marasmus	Kwashiorkor
Cause	Total calorie deficiency	Severe protein deficiency (with adequate calories)
Edema	Absent	Characteristic, peripheral
Weight	<60% expected	60-80% expected (masked by edema)
Muscle wasting	Severe ("old man" facies)	Present but masked
Skin	Wrinkled, loose folds	Flaky paint dermatosis, alternating hypo/hyperpigmentation
Hair	Thin, sparse	Depigmented, easily pluckable (flag sign)
Face	Monkey/old man facies	Moon face
Mood	Alert, irritable	Apathetic, irritable
Fatty liver	Absent	Present (from altered lipoprotein metabolism)

Pathophysiology

Marasmus = "adapted starvation" - the body adapts by reducing basal metabolic rate; insulin is low, cortisol and growth hormone are raised, promoting fat and muscle catabolism for energy
Kwashiorkor = "non-adapted starvation" - aflatoxin exposure, oxidative stress, free radical damage; low albumin causes edema; fatty liver results from failure to synthesize VLDL

Complications

Infections (impaired cell-mediated immunity)
Hypothermia
Hypoglycemia (emergency)
Electrolyte imbalances (K+, Mg2+, PO4 deficient)
Refeeding syndrome (dangerous - hypophosphatemia, hypokalemia on refeeding)
Vitamin A deficiency (xerophthalmia, blindness)
Anemia
Developmental delay

Assessment

Weight-for-height <-3 SD (Severe acute malnutrition)
MUAC (Mid-Upper Arm Circumference) <11.5 cm = SAM
Bilateral pitting edema = SAM regardless of weight
Biochemistry: hypoalbuminemia, hypoglycemia, electrolyte derangements

Management - WHO 10 Steps

Treat/prevent hypoglycemia (10% glucose, 50 mL bolus)
Treat/prevent hypothermia
Treat/prevent dehydration (oral ReSoMal - rehydration solution for malnourished)
Correct electrolyte imbalance (K+ and Mg2+ supplementation)
Treat/prevent infections (amoxicillin or cotrimoxazole)
Correct micronutrient deficiencies (Vitamin A, zinc, folate, copper)
Cautious refeeding (F-75 formula first - 75 kcal/100 mL)
Achieve catch-up growth (F-100 formula - 100 kcal/100 mL)
Provide sensory stimulation and emotional support
Prepare for follow-up after recovery

Sources: Robbins Pathology; Sleisenger & Fordtran's GI and Liver Disease

Q3. Write a note on Febrile Seizures - definition, classification, recurrence risk, and management.

Definition

Febrile seizures are epileptic seizures occurring in children between 3 months and 6 years of age, associated with fever (>38°C), without evidence of CNS infection, metabolic cause, or prior afebrile seizures. They are the most common seizure disorder in children, affecting 2-5% of the pediatric population.

Classification

Feature	Simple Febrile Seizure	Complex Febrile Seizure
Duration	<15 minutes	>15 minutes
Type	Generalized tonic-clonic	Focal features or lateralized postictal weakness
Recurrence	Single episode per illness	More than one seizure in 24 hours / same illness

Etiology

Most commonly triggered by rapid rise in temperature (viral infections most common - HHV-6, influenza)
Genetic predisposition - first-degree relative with febrile seizures increases risk
Daycare attendance increases risk (exposure to febrile illness)

Recurrence Risk

30-40% will have at least one recurrence
Predictors of recurrence:
- Age of onset <1 year
- Family history of febrile seizures in first-degree relatives
- Attendance at daycare
- Low-grade fever at time of first seizure

Risk of Epilepsy

Overall risk of epilepsy after simple febrile seizure: 1-2% (slightly higher than general population)
Risk increases with complex features:
- 1 complex feature: 6-8%
- 2 complex features: 17-22%
- All 3 complex features: 49%
Pre-existing neurodevelopmental abnormalities significantly increase risk

Management

Acute management:

ABCs (airway, breathing, circulation)
Lay child on side (recovery position)
Time the seizure
If seizure >5 minutes: Diazepam IV/rectal 0.3-0.5 mg/kg or Midazolam intranasal/buccal
If seizure continues: Lorazepam, then Phenytoin, then consider intubation
Antipyretics (paracetamol, ibuprofen) to control fever - but do NOT prevent recurrence

Investigations: Generally not required for typical simple febrile seizure. Consider LP if meningism signs, <18 months, or prolonged/complex seizure.

Long-term: No routine anticonvulsant prophylaxis for simple febrile seizures. Parental education and reassurance are key.

Source: Bradley and Daroff's Neurology in Clinical Practice

Q4. Describe Hyaline Membrane Disease (Neonatal Respiratory Distress Syndrome) - pathophysiology, clinical features, and management.

Definition

Hyaline Membrane Disease (HMD) or Neonatal RDS is a respiratory disorder of premature newborns caused by deficiency of pulmonary surfactant, leading to alveolar collapse, hypoxemia, and respiratory failure.

Surfactant Physiology

Surfactant is produced by Type II pneumocytes from about 24 weeks gestation, reaching adequate levels by 34-36 weeks
Composition: Dipalmitoylphosphatidylcholine (DPPC) is the major component, along with surfactant proteins SP-A, SP-B, SP-C, SP-D
Function: Reduces alveolar surface tension, prevents collapse at end-expiration, maintains FRC

Risk Factors

Prematurity (<34 weeks) - most important
Male sex
Maternal diabetes (insulin delays surfactant maturation)
Cesarean section without labor (labor stimulates surfactant release)
Second twin
Perinatal asphyxia

Protective factors: Maternal corticosteroids, prolonged rupture of membranes, intrauterine growth restriction

Pathophysiology

Surfactant deficiency → Increased alveolar surface tension → Alveolar collapse at end-expiration → Decreased lung compliance → Increased work of breathing → Hypoxemia + hypercapnia → Pulmonary vasoconstriction → Right-to-left shunting → Worsening hypoxemia

Clinical Features - Silverman-Andersen Scoring

Onset within first 6 hours of life (earlier = more severe):

Classic signs:

Tachypnea (RR >60/min) - from chemoreceptor stimulation by hypoxia/acidosis
Subcostal and intercostal retractions - due to very negative intrapleural pressure attempts against non-compliant lungs
Nasal flaring - accessory inspiratory muscle activation
Expiratory grunting - glottis closure to maintain pseudo-FRC, preventing complete alveolar collapse
Cyanosis - central, reflecting hypoxemia

Investigations

CXR: "Ground glass" or "reticulogranular" opacities; air bronchograms; white-out in severe cases
Blood gas: Hypoxemia (PaO2 <50 mmHg), hypercapnia, respiratory acidosis
Lecithin:Sphingomyelin (L:S) ratio <2:1 indicates lung immaturity (antenatal test)

Management

Antenatal prevention:

Betamethasone/dexamethasone 12 mg IM x 2 doses (24-48 hrs before delivery if <34 weeks) - induces surfactant synthesis

Postnatal treatment:

Oxygen therapy - maintain SpO2 91-95%
CPAP (Continuous Positive Airway Pressure) - first-line respiratory support; prevents alveolar collapse
Exogenous surfactant replacement (Poractant alfa, Beractant) - via endotracheal tube; dramatic improvement
- INSURE technique: INtubate, SURfactant, Extubate to CPAP
Mechanical ventilation - for severe cases; use lung-protective ventilation (low tidal volumes)
Supportive: Thermal regulation, IV fluids, antibiotics, caffeine for apnea of prematurity

Complications

Pneumothorax, pulmonary interstitial emphysema
Intraventricular hemorrhage
Necrotizing enterocolitis
Retinopathy of prematurity
Bronchopulmonary dysplasia (chronic lung disease) - long-term complication

Source: Medical Physiology (Boron & Boulpaep)

Q5. Describe Nephrotic Syndrome in children - types, clinical features, investigations, and management.

Definition

Nephrotic syndrome is characterized by the tetrad of:

Massive proteinuria (>40 mg/m²/hr or protein:creatinine ratio >2 or 3+ on dipstick)
Hypoalbuminemia (<2.5 g/dL)
Generalized edema (anasarca)
Hyperlipidemia and lipiduria

Epidemiology

Idiopathic nephrotic syndrome of childhood is the most common form, representing approximately 90% of cases between ages 1 and 10 years. Peak incidence is 2-5 years, with male preponderance (2:1).

Pathology - Types

Type	Frequency in children	Steroid response
Minimal Change Disease (MCD)	~80%	Usually steroid-sensitive
Focal Segmental Glomerulosclerosis (FSGS)	~10%	Often steroid-resistant
Membranoproliferative GN	~5%	Variable
Membranous nephropathy	Rare in children	Variable

Minimal Change Disease: Light microscopy normal; electron microscopy shows effacement of podocyte foot processes; thought to involve T-cell dysfunction releasing a circulating "permeability factor."

Pathophysiology of Edema - "Underfill" Theory

Proteinuria → Hypoalbuminemia → Reduced oncotic pressure → Fluid leaks into interstitium → Hypovolemia → Activation of RAAS + ADH + sympathetic system → Na+ and water retention → Edema

Clinical Features

Periorbital edema (earliest, most noticeable in morning)
Scrotal/labial edema
Ascites, pleural effusion
Anasarca in severe cases
Frothy urine (proteinuria)
Pallor
May have hypertension and hematuria (more suggestive of nephritic component)

Investigations

Urine: 3+ or 4+ protein; hyaline/granular casts; lipid droplets ("oval fat bodies")
Serum albumin: <2.5 g/dL
Serum cholesterol/triglycerides: elevated
Serum complement (C3): Normal in MCD (low in MPGN, SLE)
Renal biopsy: Indicated for age <1 year, >12 years, steroid resistance, frequent relapses, secondary causes

Management

First-line: Prednisolone

Initial: 2 mg/kg/day (max 60 mg/day) for 4 weeks
Then: 1.5 mg/kg alternate-day for 4 weeks, then taper

Response definitions:

Remission: Urine protein <1+ for 3 consecutive days
Relapse: Return to 3+ for 3 days after remission
Steroid-resistant: No remission after 8 weeks of steroids → biopsy
Frequent relapse: ≥2 relapses in 6 months or ≥4 relapses in 1 year

For frequent relapses/steroid-dependence:

Cyclophosphamide (2-3 mg/kg/day x 8-12 weeks)
Levamisole (2.5 mg/kg on alternate days)
Calcineurin inhibitors (cyclosporine, tacrolimus)
Mycophenolate mofetil
Rituximab (anti-CD20, for refractory cases)

Supportive:

Salt restriction, diuretics (furosemide) for edema
Prophylactic penicillin (Streptococcus pneumoniae is most common infection)
Pneumococcal vaccination before steroid therapy
Anticoagulation if albumin <2 g/dL (thrombosis risk)

Complications

Infections: Most common cause of death (peritonitis, sepsis - Streptococcus pneumoniae, Gram-negatives)
Thrombosis: Renal vein thrombosis, pulmonary embolism (loss of antithrombin III, protein C, S; elevated clotting factors)
Hypovolemia: Shock (more common in cases with low serum albumin)
Dyslipidemia: Accelerated atherosclerosis

Source: The Harriet Lane Handbook, 23rd Edition

Q6. Enumerate the causes of stridor in children and discuss the management of croup.

Stridor - Definition

Stridor is a high-pitched harsh sound produced by turbulent airflow through a partially obstructed airway. It is a symptom, not a diagnosis.

Classification by Phase

Inspiratory stridor: Supraglottic/glottic obstruction (most common)
Expiratory stridor: Intrathoracic airway obstruction (wheeze-like)
Biphasic stridor: Subglottic/upper tracheal obstruction (most serious)

Causes by Age

Neonates/Infants:

Laryngomalacia (most common cause of stridor in infants - "floppy larynx")
Subglottic stenosis
Tracheomalacia
Vascular ring
Hemangioma

Toddlers (1-3 years):

Croup (Laryngotracheobronchitis) - most common
Foreign body aspiration
Bacterial tracheitis

Older children:

Epiglottitis (Haemophilus influenzae type b - now rare due to Hib vaccine)
Retropharyngeal abscess
Peritonsillar abscess
Diphtheria (membranous laryngotracheitis)

Croup (Laryngotracheobronchitis)

Etiology: Parainfluenza virus type 1 (most common), type 3, RSV, influenza

Age: 6 months - 3 years; peak in autumn

Pathology: Subglottic edema and inflammation; subglottic space is the narrowest part in children (cartilaginous cricoid ring), so small degrees of swelling cause significant obstruction

Clinical Features:

Gradual onset, low-grade fever, URI symptoms
Barking/seal-like cough (characteristic)
Inspiratory stridor (worsens with agitation)
Hoarseness
Steeple sign on AP X-ray neck (subglottic narrowing)

Severity - Westley Croup Score:

Score	Severity
0-1	Mild
2-7	Moderate
8-11	Severe
≥12	Impending respiratory failure

Management of Croup:

Mild (score 0-2):

Supportive care at home
Dexamethasone 0.15 mg/kg oral (single dose - reduces duration and severity)
Humidified air (limited evidence but commonly practiced)
Oral fluids

Moderate (score 3-7):

Oral/IM dexamethasone 0.6 mg/kg (single dose)
Nebulized budesonide 2 mg (if oral not tolerated)
Observe for 3-4 hours

Severe (score ≥8):

Nebulized adrenaline/epinephrine 5 mL of 1:1000 - immediate relief (effect lasts 2-3 hours; watch for rebound)
Dexamethasone 0.6 mg/kg IM/IV
Oxygen supplementation
ICU admission, prepare for intubation/tracheostomy

Differentiating Croup from Epiglottitis:

Feature	Croup	Epiglottitis
Age	6 months - 3 years	2-8 years
Onset	Gradual	Rapid
Cough	Barking	Absent or minimal
Position	Any	Tripod (leaning forward)
Drooling	Absent	Present
X-ray	Steeple sign (neck AP)	Thumb sign (lateral)
Organism	Parainfluenza virus	H. influenzae b

Q7. Define and classify dehydration in children. Describe the management of acute gastroenteritis with dehydration.

Dehydration - Definition

Dehydration is a state of excessive loss of body water and electrolytes. In children, diarrhea is the most common cause.

Classification by Severity (WHO)

Feature	No dehydration	Some dehydration	Severe dehydration
Condition	Alert	Irritable/restless	Lethargic/unconscious
Eyes	Normal	Sunken	Very sunken
Thirst	Drinks normally	Drinks eagerly	Drinks poorly/unable
Skin pinch	Goes back quickly	Slow (<2 sec)	Very slow (>2 sec)

Classification by Tonicity

Isotonic (80%): Equal loss of water and sodium (Na 130-150 mEq/L)
Hypotonic: Na loss > water loss (Na <130) - more intravascular; presents rapidly
Hypertonic: Water loss > Na loss (Na >150) - cells dehydrate; risk of cerebral edema on rehydration

Assessment

Weight: Most accurate measure of fluid deficit
Estimated % dehydration:
- <5% = Mild (not clinically detectable)
- 5-10% = Moderate (signs present)
- 10% = Severe (shock, unresponsive)

Management of Acute Gastroenteritis

Plan A - No dehydration:

Continue breast feeding and feeding
ORS 10 mL/kg after each loose stool
Zinc supplementation (10-20 mg/day for 14 days)

Plan B - Some dehydration:

ORS 75 mL/kg over 4 hours (WHO low-osmolarity ORS: Na 75 mEq/L, K 20 mEq/L, Glucose 75 mmol/L, Osmolarity 245)
Reassess after 4 hours
If improving → Plan A; if worse → Plan C

Plan C - Severe dehydration:

Ringer's Lactate or Normal Saline 20 mL/kg IV bolus over 15-30 minutes
Repeat if no improvement in perfusion
Once conscious: transition to ORS
Total fluid deficit replaced over 24 hours (first half in 8 hours, remaining in 16 hours)
Maintenance fluids added on top

ORS Composition (WHO low-osmolarity):

Sodium chloride: 2.6 g/L
Trisodium citrate: 2.9 g/L
Potassium chloride: 1.5 g/L
Glucose: 13.5 g/L
Osmolarity: 245 mOsm/L

Adjuncts:

Zinc (10 mg <6 months, 20 mg ≥6 months for 14 days) - reduces duration and recurrence
Probiotics (some benefit)
Antibiotics - NOT routinely given; use only for cholera, Shigella dysentery, enteric fever
Anti-motility drugs (loperamide) - contraindicated in children

Q8. Discuss Respiratory Syncytial Virus (RSV) Bronchiolitis in infants - pathophysiology, clinical features, and management.

Definition

Bronchiolitis is an acute inflammatory disease of the small airways (bronchioles) in children <2 years of age, most commonly caused by RSV. It is the most common cause of hospitalization in infants.

Epidemiology

Peak incidence: 2-6 months of age
Seasonal: Winter/autumn (RSV season)
RSV responsible for 60-80% of cases; others: parainfluenza, rhinovirus, human metapneumovirus, adenovirus

Pathophysiology

RSV infects bronchiolar epithelium → Viral shedding + inflammatory cell infiltration → Edema, mucus hypersecretion, epithelial cell necrosis → Partial obstruction of bronchioles → Air trapping (hyperinflation), atelectasis → Ventilation-perfusion mismatch → Hypoxemia

Clinical Features

Early (viral URI phase - 1-3 days):

Rhinorrhea, nasal congestion, low-grade fever
Cough (initially dry, then wet/productive)

Late (bronchiolar obstruction phase - day 3-7):

Tachypnea (most reliable sign - RR >60 in <2 months, >50 in 2-12 months)
Subcostal and intercostal retractions
Nasal flaring
Diffuse fine crackles on auscultation (characteristic of bronchiolitis)
High-pitched wheeze (expiratory and/or inspiratory)
Hyperinflation: Increased AP diameter, hyperresonant percussion, displaced liver
Cyanosis and apnea in severe cases (especially preterm infants)

Investigations

CXR: Hyperinflation, peribronchial thickening, patchy atelectasis
Nasopharyngeal swab: RSV antigen detection (rapid immunofluorescence), PCR
Blood gas: Hypoxemia, hypercapnia in severe cases
Not required routinely: blood count, blood culture

Severity Assessment - RDAI (Respiratory Distress Assessment Instrument)

Indications for hospitalization:

SpO2 <92% on room air
RR >70/min (infants), apnea
Severe retractions, nasal flaring
Unable to feed (>50% decrease)
Age <3 months or corrected age <44 weeks for preterm
Toxic appearance

Management - Largely Supportive

Supportive (mainstay):

Oxygen - to maintain SpO2 >92%
Hydration - IV fluids or nasogastric feeds if unable to feed orally
Positioning - head elevated at 30 degrees
Nasal suctioning - clear secretions

High-flow nasal cannula (HFNC): Standard of care for moderate-severe disease; reduces work of breathing significantly.

NOT routinely recommended:

Bronchodilators (salbutamol, ipratropium) - no evidence of benefit
Nebulized epinephrine - no long-term benefit, short-term effect only in hospital
Corticosteroids - not effective
Antibiotics - not indicated unless secondary bacterial pneumonia
Ribavirin - not routinely used

Prevention:

Palivizumab (RSV monoclonal antibody): Monthly IM injections for high-risk infants (preterm <29 weeks, chronic lung disease, congenital heart disease) during RSV season

Q9. Discuss Vitamin D Deficiency Rickets in children - etiology, clinical features, and management.

Introduction

Rickets is the disorder of growing bone in children due to failure of mineralization of osteoid. The most common cause is Vitamin D deficiency. Osteomalacia is the adult equivalent.

Vitamin D Metabolism

Sun (UV-B) → Skin converts 7-dehydrocholesterol → Cholecalciferol (D3) → Liver hydroxylation → 25(OH)D3 (calcidiol) → Kidney hydroxylation (1-alpha hydroxylase) → 1,25(OH)2D3 (calcitriol) - active form

Causes of Rickets

Nutritional Vitamin D deficiency - most common globally (dark skin, exclusive breastfeeding without supplementation, poor sun exposure)
Calcium deficiency rickets - dietary calcium deficiency (common in Africa)
Vitamin D-dependent rickets Type I - 1-alpha hydroxylase deficiency (AR)
Vitamin D-dependent rickets Type II - VDR mutation (AR)
Hypophosphatemic rickets (X-linked dominant) - PHEX gene mutation, FGF23 excess
Renal osteodystrophy - chronic kidney disease

Pathophysiology

Vitamin D deficiency → Reduced intestinal Ca and P absorption → Hypocalcemia → PTH increases (secondary hyperparathyroidism) → PTH mobilizes Ca from bone → Increased renal Ca reabsorption + Phosphaturia → Hypophosphatemia → Failure of bone mineralization → Rickets

Clinical Features

Bony deformities:

Craniotabes - softening of occipital bones in infants (earliest sign)
Frontal bossing - prominence of frontal and parietal bones
Rachitic rosary - beading of costochondral junctions
Harrison's sulcus - horizontal groove at lower chest margin (diaphragm pull)
Pigeon chest (pectus carinatum) or funnel chest (pectus excavatum)
Genu varum (bow legs) - more common in toddlers
Genu valgum (knock knees) - more common in older children
Coxa vara (waddling gait)
Enlarged wrists and ankles (metaphyseal widening)
Delayed fontanelle closure and delayed dentition

Other features:

Muscle hypotonia ("frog-leg" posture)
Pot belly (weak abdominal muscles)
Delayed motor milestones
Hypocalcemia symptoms: Tetany (Chvostek's sign, Trousseau's sign), seizures, stridor (laryngospasm)
Growth retardation
Increased susceptibility to infections

Investigations

Test	Finding
Serum 25(OH)D	<20 ng/mL (deficient)
Serum Ca	Low or normal
Serum Phosphate	Low
Serum ALP	High (most sensitive marker)
PTH	Elevated
X-ray wrist	Cupping, fraying, splaying of metaphysis; widened growth plate
X-ray long bones	Pathologic fractures (Looser's zones in adults)

Management

Vitamin D3 (Cholecalciferol):
- Therapeutic dose: 1,500-5,000 IU/day for 3 months, then maintenance
- Stoss therapy (for compliance): 3-6 lakh IU as single oral dose
Calcium supplementation: 30-75 mg/kg/day elemental calcium
Sunlight exposure counseling
Treat underlying cause in secondary rickets
Orthopedic correction - only after biochemical healing; surgical correction for persistent deformities

Prevention:

Vitamin D 400 IU/day for all breastfed infants from birth
Maternal Vitamin D supplementation in pregnancy

Q10. Write a short note on the National Immunization Schedule (NIS) of India - vaccines, schedule, and cold chain.

Introduction

Immunization is the administration of vaccines to develop active or passive immunity against infectious diseases. The Universal Immunization Programme (UIP) of India provides free vaccines at government facilities.

National Immunization Schedule - India (UIP 2025)

Age	Vaccine(s)
Birth	BCG, Hepatitis B (1st dose), OPV-0 (Zero dose)
6 weeks	OPV-1, IPV-1, Pentavalent-1 (DPT+HBV+Hib), Rotavirus-1, PCV-1
10 weeks	OPV-2, IPV-2, Pentavalent-2, Rotavirus-2, PCV-2
14 weeks	OPV-3, IPV-3, Pentavalent-3, Rotavirus-3, PCV-3
6 months	Vitamin A (1st dose)
9 months	MR vaccine (Measles-Rubella), Vitamin A (2nd dose), JE vaccine (endemic areas)
12 months	PCV booster
15-18 months	MR 2nd dose, DPT booster-1, OPV booster
16-24 months	Vitamin A (doses 3 to 9, every 6 months)
5-6 years	DPT booster-2
10 years	Td (Tetanus + low-dose Diphtheria)
16 years	Td

Important Vaccines - Key Points

BCG:

Bacille Calmette-Guerin (live attenuated Mycobacterium bovis)
Given at birth, intradermal, left deltoid
Protects against severe/disseminated TB in children (miliary TB, TB meningitis)
PPD test becomes positive after 6-8 weeks

OPV (Oral Polio Vaccine):

Live attenuated Sabin vaccine
Contains types 1, 2, 3 (trivalent) or bivalent (types 1 and 3 currently)
Type 2 removed from routine OPV post global eradication of wild type 2
Advantage: Gut immunity, herd immunity via fecal-oral spread
Risk: VAPP (Vaccine-Associated Paralytic Polio) - 1 in 1-2.4 million first doses

IPV (Inactivated Polio Vaccine):

Salk vaccine, injectable
No risk of VAPP
India uses fractional IPV (fIPV) intradermally - 0.1 mL ID at 6 and 14 weeks

Pentavalent Vaccine (DPT + HBV + Hib):

3 doses at 6, 10, 14 weeks
DPT: Whole-cell pertussis (wP) in UIP; acellular (aP) in private sector
Hib: Haemophilus influenzae type b - prevents meningitis, epiglottitis, pneumonia

MR/MMR:

Live attenuated Measles-Rubella vaccine in UIP
MMR (Measles-Mumps-Rubella) in private sector
Two doses required for adequate protection

Cold Chain

Vaccines must be stored at specified temperatures to maintain potency:

-15° to -25°C: OPV, Varicella, MMR
+2° to +8°C: BCG, DPT, Hepatitis B, Pentavalent, IPV, PCV
Never freeze Hepatitis B, Pentavalent, IPV - freeze sensitivity

Cold chain equipment:

Walk-in freezer/cooler (national/state stores)
ILR (Ice-Lined Refrigerator) - district/PHC level
Deep freezer - for OPV
Vaccine carrier with ice packs - field immunization
Cold boxes for transport

Shake test: For potentially frozen vaccines (HBV, DPT, Pentavalent) - if shaken with ice and settles like control → safe; if flocculates faster → frozen = discard

Contraindications

BCG: Immunodeficiency, HIV symptomatic
Live vaccines (OPV, MMR, BCG): Immunocompromised states, high-dose steroids, malignancy
DPT: Encephalopathy within 7 days of previous DPT dose (give DT instead)
Egg allergy: MMR can still be given (trace amounts, but safe per current guidelines)

Study tip for MBBS finals: For 10-mark questions, always follow the DICE structure: Definition/Introduction, Investigations/Etiology, Clinical features, End with Management/Complications/Prevention. Examiners award marks for subheadings, tables, and clinical diagrams - always include those.

Primary sources: Rosen's Emergency Medicine; Bradley & Daroff's Neurology; The Harriet Lane Handbook 23rd Ed; Robbins & Kumar Pathology; Medical Physiology (Boron & Boulpaep); Park's Preventive and Social Medicine

This is a shared conversation. Sign in to Orris to start your own chat.